PBAC's latest decision on Secukinumab: Recommended with restriction (2023). Considered for Treatment of moderate to severe hidradenitis suppurativa in adult patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
11
first 2015
PBS spend
$104M
75,495 scripts · 2024
Eligible population
Adult patients with moderate to severe hidradenitis suppurativa (Hurley stage II or III with ≥3 abscess and inflammatory nodule count) who have failed 2 courses of different antibiotics each for 3 months or have contraindications/adverse reactions to antibiotics.
Therapy area
Dermatology
Line of therapy
Second-line
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
adalimumab
Economic model
Cost-minimisation
Budget impact
$20M
ICER note
Cost minimisation analysis; no ICER calculated as this is a cost-minimisation comparison.
PBS expenditure
The Australian government paid $104M in PBS benefits for Secukinumab in 2024 across 75,495 scripts, at $1,376 per script.
Submission history
Mar 2015: Recommended · Authority Required
Mar 2016: Recommended with restriction · Authority Required
Mar 2016: Recommended with restriction · Authority Required
Mar 2016: Recommended with restriction · Restricted
Jul 2017: Not recommended · Restricted
Nov 2020: Recommended with restriction · Authority Required
Jul 2021: Not recommended · Authority Required
Nov 2021: Recommended with restriction · Authority Required
Mar 2022: Recommended · Authority Required
Jul 2023: Recommended with restriction · Authority Required
Nov 2023: Recommended with restriction · Authority Required